4D Molecular Therapeutics, Inc. (FDMT) Free cash flow 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$109.6MFY2025 · since FY2019: -$39.9M → -$109.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$109.6M | +20.8% |
| FY2024 | -$138.4M | -76.1% |
| FY2023 | -$78.6M | +20.0% |
| FY2022 | -$98.2M | -25.5% |
| FY2021 | -$78.2M | -50.7% |
| FY2020 | -$51.9M | -30.1% |
| FY2019 | -$39.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice